FoCUS

Focus Therapeutics is a biopharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and inflammatory diseases. The company leverages its expertise in medicinal chemistry and biology to target key signaling pathways involved in disease progression, such as the IRAK4 and BET protein families. Focus Therapeutics aims to develop highly selective and potent inhibitors that can address significant unmet medical needs in oncology and autoimmune disorders. Currently, the company's pipeline is primarily in the pre-clinical stage, focusing on optimizing lead candidates for future clinical evaluation.